1. Scrip

Amgen/KK’s Atopic Dermatitis Deal Shows OX40’s Allure, But Market Still Tough

Amgen will pay $400m upfront and up to $850m in milestones

 
• By Alaric DeArment

Amgen said Phase II data are planned for the EADV 2021 meeting, but KHK4083 will need a strong showing.

Dermatitis
Amgen and Kyowa Kirin have signed a deal to develop and commercialize OX40 inhibitor KHK4083 for atopic dermatitis. • Source: Shutterstock

Amgen, Inc. paying up to $1.25bn for Kyowa Kirin Co., Ltd.’s OX40-targeting KHK4083 in atopic dermatitis marks a significant vote of confidence in a new mechanism of action for a disease in a highly competitive market. There is still unmet need, however, but with a wide variety of therapeutic options approved or in late-stage development, the OX40 inhibitor will need to prove itself when the full Phase II data become available in the second half of 2021.

Thousand Oaks, CA-based Amgen and Tokyo-based Kyowa Kirin announced the deal on 1 June to develop and commercialize KHK4083 in atopic dermatitis and other inflammatory diseases. The news follows the Japanese drug maker’s announcement in February of positive results from a Phase II study of the drug

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.